These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11926725)

  • 1. Mechanisms of weight gain induced by antipsychotic drugs.
    Baptista T
    J Clin Psychiatry; 2002 Mar; 63(3):245-6. PubMed ID: 11926725
    [No Abstract]   [Full Text] [Related]  

  • 2. Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.
    Baptista T; Lacruz A; Acosta A; Colasante C; de Quijada M; de Mendoza S; Mendoza JM; Hernández L
    Appetite; 2000 Feb; 34(1):77-86. PubMed ID: 10744894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.
    Zuo J; Liu Z; Ouyang X; Liu H; Hao Y; Xu L; Lu XH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):387-97. PubMed ID: 17935847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 5. Antipsychotic drugs and diabetes.
    McIntyre RS
    CMAJ; 2003 Mar; 168(6):673. PubMed ID: 12642417
    [No Abstract]   [Full Text] [Related]  

  • 6. [Changes in the endocrine system in the course of sulpiride therapy].
    Roś LT
    Pol Merkur Lekarski; 2001 Dec; 11(66):532-4. PubMed ID: 11899856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates.
    Baptista T; López ME; Teneud L; Contreras Q; Alastre T; de Quijada M; Araujo de Baptista E; Alternus M; Weiss SR; Musseo E; Páez X; Hernández L
    Pharmacopsychiatry; 1997 Mar; 30(2):43-54. PubMed ID: 9131724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone-associated steatohepatitis and excessive weight-gain.
    Holtmann M; Kopf D; Mayer M; Bechtinger E; Schmidt MH
    Pharmacopsychiatry; 2003 Sep; 36(5):206-7. PubMed ID: 14571356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
    Kostulski A; Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
    Przegl Lek; 2005; 62(9):938-43. PubMed ID: 16541734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive akathisia due to sulpiride.
    López de Munain A; Poza JJ; Gorospe A; Arce A; Martí Massó JF
    Clin Neuropharmacol; 1994 Oct; 17(5):481-3. PubMed ID: 9316700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meige syndrome with apraxia of lid opening after the discontinuation of sulpiride treatment.
    Tsuji S; Kikkawa S; Horiguchi J; Yamashita H; Kagaya A; Morinobu S; Yamawaki S
    Pharmacopsychiatry; 2002 Jul; 35(4):155-6. PubMed ID: 12163987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.
    Fell MJ; Neill JC; Marshall KM
    Eur Neuropsychopharmacol; 2004 Oct; 14(5):385-92. PubMed ID: 15336300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychiatric medication-induced obesity: a review.
    Schwartz TL; Nihalani N; Jindal S; Virk S; Jones N
    Obes Rev; 2004 May; 5(2):115-21. PubMed ID: 15086865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies].
    Himmerich H; Schuld A; Pollmächer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S233-7. PubMed ID: 15586316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperprolactinemia induced by neuroleptics].
    Lakartidningen; 2007 May 9-15; 104(19):1522. PubMed ID: 17550031
    [No Abstract]   [Full Text] [Related]  

  • 18. Body weight gain induced by antipsychotic drugs: mechanisms and management.
    Baptista T
    Acta Psychiatr Scand; 1999 Jul; 100(1):3-16. PubMed ID: 10442434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and genetics of antipsychotic-associated weight gain.
    Balt SL; Galloway GP; Baggott MJ; Schwartz Z; Mendelson J
    Clin Pharmacol Ther; 2011 Jul; 90(1):179-83. PubMed ID: 21633343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.